Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with commercial insurance, which goes into effect ...

In the flap over whether Sanofi-Aventis' Lantus diabetes drug has an association with cancer, cynicism seems to be winning. Sanofi's stock (see graph) seems not to have recovered from reports that ...

Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY.Similar to Lilly, Sanofi also said it is ...

F ollowing the lead of its rivals, Sanofi will cut the price of its most widely prescribed insulin in the U.S. by 78% and also place a $35 cap on out-of-pocket costs for commercially insured ...

GoodRx has announced a collaboration with Sanofi to offer the drugmaker’s Lantus brand of insulin for $35 a month at tens of thousands of U.S. pharmacies, regardless of consumers’ insurance ...

The FDA approved Sanofi’s daily diabetes drug Toujeo Wednesday, but the new treatment does not appear to pack a profile that will pull payers or physicians away from Lantus to generic-free Toujeo.

Sanofi plans to take a 78% list-price reduction on Lantus, the company’s most widely used insulin in the U.S., and a 70% cut on its Apidra product starting in January 2024, the company said ...

Sanofi joins Eli Lilly and Novo Nordisk to cap insulin prices. President Joe Biden still wants Congress to enact limits. Amid pressure from both the public and the Biden administration, a third ...